About 400 reports

  • TOTAL SALES AS REPORTED BY AMGEN AND KHK
  • TOTAL SALES (EX-JAPAN) AS REPORTED BY AMGEN

Hoffmann-La Roche (" Roche" ) to acquire Roche' s rights to filgrastim and pegfilgrastim in approximately ## markets, effective Jan. ##, 2014.

  • Oncology
  • United States
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Neupogen group
  • Xiamen Amoytop Biotech Co Ltd
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY OCTAPHARMA AG, H2 2017

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced...

  • Chemotherapy
  • Oncology
  • United States
  • World
  • Product Initiative
  • BIOCON
  • RECOMBINANT HUMAN ERYTHROPOETIN

The global biosimilars market projected to grow at a CAGR of 31.7% during the forecast period. The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness,...

  • Monoclonal Antibody
  • Oncology
  • North America
  • United States
  • Market Size
  • Febrile Neutropenia - Dormant Projects
  • Febrile Neutropenia - Therapeutics Assessment

Febrile Neutropenia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides an overview of the Febrile Neutropenia (Hematological Disorders) pipeline landscape. Febrile neutropenia can develop...

  • Oncology
  • United States
  • World
  • Product Initiative
  • Coherus BioSciences, Inc.
  • Biocon Limited - Early Stage Pipeline Products
  • Biocon Limited - Pipeline by Indication, 2016

Biocon Limited - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Biocon Limited - Product Pipeline Review - 2016’, provides an overview of the Biocon Limited’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Biocon...

  • Insulin
  • Oncology
  • World
  • Product Initiative
  • Biocon Limited
  • XIAMEN AMOYTOP BIOTECH CO LTD
  • CHEMOTHERAPY INDUCED NEUTROPENIA - DORMANT PROJECTS, H1 2018

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2018, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced...

  • Chemotherapy
  • Oncology
  • United States
  • World
  • Product Initiative
  • undisclosed chemotherapy, topotecan hydrochloride, melphalan, filgrastim, busulfan and autologous hematopoietic stem cells alone or in combination have the highest number of nonseminomatous testicular cancer ongoing clinical trials.
  • 5. All the trials included are unique trials.

Nonseminomatous Testicular Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Nonseminomatous Testicular Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Nonseminomatous Testicular Cancer clinical trials scenario.This report provides...

  • Chemotherapy
  • Oncology
  • Therapy
  • World
  • Product Initiative

TABLE OF CONTENTS (##/ ##) ##.

  • Oncology
  • Therapy
  • World
  • Supply
  • Remicade group
  • 7.11.2 DR. REDDY'S LABORATORIES - MAJOR BIOSIMILARS APPROVED FOR MARKETING
  • Intas Pharmaceuticals major biosimilars approved for marketing are as follows:

The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020. With the continuous increasing demand for biologics,...

  • Oncology
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • Cancer Supportive Care Market, Global, Approved Indications for Neulasta, 2017
  • Cancer Supportive Care Market, Global, Approved Indications for Neupogen, 2017

Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets Summary Cancer is a disease characterized by abnormal cell growth and uncontrolled proliferation caused by a series of mutations that result in the...

  • Oncology
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • 9.14 DR. REDDY'S LABORATORIES INC.
  • 9.14 DR. REDDY'S LABORATORIES INC.

The company has received approval for tbo-filgrastim (XM## filgrastim).

  • Oncology
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • Chemotherapy-induced neutropenia

NEUPOGEN (FILGRASTIM) Cancer pain affects a large number of individuals undergoing cancer treatment.

  • Blood Disease
  • Oncology
  • Amgen Inc.
  • Helsinn Group
  • Merck & Co., Inc.
  • Drug Profiles
  • PEGFILGRASTIM - DRUG PROFILE

Filgrastim works by enhancing the activity of G-CSF receptors.

  • Biosimilar
  • Oncology
  • Research And Development
  • United States
  • Company Operations
  • Clinical Trial profile. 278 Trial Title
  • Clinical Trial profile. 236 Trial Title

Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017" provides an overview of Leukocyte Disorders (White Blood Cell Disorders)...

  • Blood Disease
  • Blood Supply
  • Clinical Trial
  • Oncology
  • World
  • Official Title
  • Clinical Trial profile. 115 Trial Title

Neutropenia Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Neutropenia Global Clinical Trials Review, H2, 2016" provides an overview of Neutropenia clinical trials scenario. This report provides top line data relating to the clinical trials on Neutropenia. Report includes an overview...

  • Blood Disease
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • Official Title
  • Official Title

Neutropenia Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Neutropenia Global Clinical Trials Review, H1, 2018" provides an overview of Neutropenia clinical trials scenario.This report provides top line data relating to the clinical trials on Neutropenia. Report...

  • Blood Disease
  • Clinical Trial
  • Drug Discovery And Development
  • Oncology
  • World
  • Hertraz (Trastuzumab)
  • RITUXIMAB

About Oncology Biosimilars Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting....

  • Oncology
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Sandoz Inc.

Filgrastim is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).

  • Monoclonal Antibody
  • Oncology
  • United States
  • World
  • Sandoz Inc.
  • Target
  • PROMINENT DRUGS

Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2017" provides an overview of Chemotherapy Induced Neutropenia clinical trials scenario. This report provides top line data relating...

  • Chemotherapy
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY BIOGENOMICS LTD
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY MYCENAX BIOTECH INC

Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 Summary This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy...

  • Neurological Disorder
  • Oncology
  • United States
  • Company
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Sarah Cannon Research Institute LLC ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ##

  • Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative
  • Clinical Trial profile. 59 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

One anti-drug antibody was observed for ALXN## and one for Soliris.

  • Clinical Trial
  • Leukemia
  • Oncology
  • Therapy
  • Alexion Pharmaceuticals, Inc.
  • Branded Name

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, the immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, end user, and region. Increasing adoption...

  • Monoclonal Antibody
  • Oncology
  • North America
  • United States
  • World
  • provides a SWOT analysis of Rolontis.
  • 7.5.2.4 SWOT Analysis

TBO-Filgrastim (Granix).

  • Oncology
  • United States
  • Amgen Inc.
  • BeyondSpring Pharmaceuticals Inc.
  • Helsinn Group
  • Clinical Trial profile. 33 Trial Title
  • Clinical Trial profile. 159 Trial Title

Lymphoblastic Lymphoma Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Lymphoblastic Lymphoma Global Clinical Trials Review, H2, 2017" provides an overview of Lymphoblastic Lymphoma clinical trials scenario. This report provides top line data relating to the clinical...

  • Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative
  • Clinical Trial profile. 1316 Trial Title
  • Clinical Trial profile. 1934 Trial Title

The prominent features of this report are - ##.

  • Leukemia
  • Monoclonal Antibody
  • Oncology
  • United States
  • World
  • Clinical Trial profile. 43 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Leukemia
  • Oncology
  • World
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Monoclonal Antibody
  • Oncology
  • World
  • Product Initiative

Consequent to the approval of Novartis' Filgrastim biosimilar in the US-the first biosimilar to receive FDA approval-it is expected that the focus on biosimilars will increase in the country.

  • Oncology
  • North America
  • United States
  • World
  • Horizon Discovery
  • Clinical Trial profile. 14 Trial Title

Hoffmann-La Roche Ltd arGEN-X BV ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Applied BioMath LLC ## ## ## ## ## Amgen Inc ## ## ## ## ## Almirall SA Source: GlobalData' s Pharma Intelligence C

  • Autoimmune Disease
  • Oncology
  • Pharmaceutical
  • World
  • Product Initiative